Two stocks in Healthcare
Bristol-Myers Squibb vs Regeneron Pharmaceuticals: profit, growth, debt and price compared
Regeneron Pharmaceuticals is stronger on 4 of 7 figures: profit margin, sales growth, debt and price trend. Bristol-Myers Squibb is stronger on 2: price for its expected profit and dividend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Bristol-Myers SquibbBMY | Regeneron PharmaceuticalsREGN | |
|---|---|---|
| Net margin | 18.5% | Stronger: 28.5% |
| Revenue growth, past year | +6.93% | Stronger: +36.27% |
| Debt to equity | 191.5% | Stronger: 8.1% |
| Forward P/E | Stronger: 8.9× | 13.3× |
| Dividend yield | Stronger: 4.23% | 0.39% |
| Analysts | Buy · 24 | Buy · 27 |
| From its 200-day average | +1.2% | Stronger: +24.2% |
Share price over the past year
- Bristol-Myers Squibb+26.6%
- Regeneron Pharmaceuticals+30.4%
18 Nov 202518 Nov 2026
Bristol-Myers Squibb or Regeneron Pharmaceuticals: which is stronger?
- REGN
Which is more profitable?
Regeneron Pharmaceuticals keeps more of each sale as profit: 28.5% against 18.5%.
- REGN
Which is growing its sales faster?
Regeneron Pharmaceuticals is growing its sales faster: +36.27% over the past year, against +6.93%.
- REGN
Which has borrowed less?
Regeneron Pharmaceuticals has borrowed less: its debt is 8.1% of what its shareholders own, against 191.5% for Bristol-Myers Squibb.
- BMY
Which costs less for the profit it is expected to make?
Bristol-Myers Squibb costs less for the profit it is expected to make: 8.9× its forward earnings, against 13.3×.
- BMY
Which pays more in dividends?
Bristol-Myers Squibb pays more back in dividends for what a share costs: 4.23% a year, against 0.39%.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- REGN
Which is in the stronger price trend?
Regeneron Pharmaceuticals' price is in the stronger trend: 24.2% above its 200-day average, against 1.2% above.
What each company does
BMYBristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Reports results on 4 February 2027
REGNRegeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Reports results on 28 January 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.